29.96

0.95% 0.50

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $29.96, with a volume of 1.17M. It is up +0.95% in the last 24 hours and up +47.08% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Previous Close:

$29.46

Open:

$29.12

24h Volume:

1.17M

Relative Volume:

0.29

Market Cap:

$4.88B

Revenue:

$56.99M

Net Income/Loss:

$-107.23M

P/E Ratio:

-36.54

EPS:

-0.8199

Net Cash Flow:

$-142.55M

1W Performance:

-8.66%

1M Performance:

+47.08%

6M Performance:

+207.55%

1Y Performance:

+421.75%

1-Day Range:

$29.01

$30.31

1-Week Range:

$28.60

$33.53

52-Week Range:

$5.34

$34.39

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1097)

Industry

Biotechnology (615)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

137

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	29.98	5.09B	56.99M	-107.23M	-142.55M	-0.8199
VRTX Vertex Pharmaceuticals Inc	528.70	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	647.99	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	926.39	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.73	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.24	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-26	Initiated	Canaccord Genuity	Buy
Feb-23-26	Initiated	Mizuho	Outperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Aug-19-25	Initiated	Piper Sandler	Overweight
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

Jun 30, 2026

TNGX Q1 2026 Earnings: Net Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances PipelineHigh Growth Earnings - dars.gov.et

Jun 30, 2026

TNGX Maintained by Canaccord Genuity -- Price Target Raised to $46 - GuruFocus

Jun 30, 2026

Jun 29, 2026

Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat

Jun 29, 2026

Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 29, 2026

Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Enterprise value to revenue forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView

Jun 27, 2026

Jun 26, 2026

Enterprise value to EBITDA forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView

Jun 26, 2026

Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60 - Moomoo

Jun 26, 2026

Enterprise value to EBIT forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView

Jun 25, 2026

Jefferies upgrades Tango Therapeutics stock rating on cancer trial data By Investing.com - Investing.com Nigeria

Jun 25, 2026

Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60 - Moomoo

Jun 25, 2026

Jefferies upgrades Tango Therapeutics stock rating on cancer trial data - Investing.com

Jun 25, 2026

TNGX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Why is Tango Therapeutics stock surging today? By Investing.com - Investing.com Nigeria

Jun 25, 2026

Price to sales forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView

Jun 25, 2026

Jun 23, 2026

Form 8K Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com Australia

Jun 23, 2026

Form 4 Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa

Jun 23, 2026

Director at Tango Therapeutics (TNGX) receives RSUs and stock options - Stock Titan

Jun 23, 2026

New Tango Therapeutics (TNGX) director Robert Azelby files initial Form 3 - Stock Titan

Jun 23, 2026

Robert Azelby appointed to Tango Therapeutics board, joins Compensation and NCG Committees - TradingView

Jun 23, 2026

Biotech veteran Robert Azelby joins Tango Therapeutics (TNGX) board as company advances vopimetostat - Stock Titan

Jun 23, 2026

Positive trial data lifts forecasts for Tango Therapeutics’ oncology program - S&P Global

Jun 23, 2026

Tango Therapeutics Appoints New Board Member - Intellectia AI

Jun 23, 2026

Tango Therapeutics Company Profile & Introduction - Moomoo

Jun 23, 2026

Jun 22, 2026

Tango Therapeutics appoints Robert Azelby to board of directors By Investing.com - Investing.com South Africa

Jun 22, 2026

Tango Therapeutics appoints Robert Azelby to board of directors - Investing.com

Jun 22, 2026

Tango Therapeutics Appoints Robert Azelby to Board of Directors - The Manila Times

Jun 22, 2026

Press Release: Tango Therapeutics Appoints Robert Azelby to Board of Directors - Moomoo

Jun 22, 2026

Tango Therapeutics files for $500 million common stock offering - MSN

Jun 22, 2026

Jun 20, 2026

ACUTA CAPITAL PARTNERS, LLC's Tango Therapeutics Inc(TNGX) Holding History - GuruFocus

Jun 20, 2026

Jun 19, 2026